Is MMSI a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Merit Medical Systems (MMSI) rests on Organic growth in interventional devices: Merit's core peripheral intervention, cardiac intervention, and interventional oncology lines serve procedures that continue to shift toward minimally invasive approaches. The bear case rests on merit competes against far larger and better-capitalized device companies including Boston Scientific, Medtronic, Abbott, Teleflex, Becton Dickinson, and Terumo, which can pressure pricing and share. Analysts covering it publish targets from $74.00 to $110.00 against a $79.38 price, so even the professionals disagree by 40% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Merit Medical Systems designs, manufactures, and markets a broad catalog of single-use and capital medical devices used in minimally invasive procedures. Its business splits into two segments: Cardiovascular (peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care) and Endoscopy (non-vascular stents, balloon dilators, and related tools for gastroenterologists and pulmonologists). The company sells globally through direct sales forces and distributors, and it has grown revenue toward roughly $1.5 to $1.6 billion annually, driven by a mix of organic volume and frequent product-line acquisitions. The investment picture is one of a steady compounder rather than a high-growth story. Merit converts single-digit revenue growth into faster non-GAAP EPS growth through margin expansion, and it trades at a premium medical-device multiple that reflects its consistency and acquisition track record. The picture also carries typical med-tech considerations: tariff and input-cost pressure on gross margin, reliance on M&A to sustain growth, and competition against much larger diversified device companies.
The bull case: what would have to be true for $110.00
The most optimistic published target on MMSI is $110.00, +38.6% from the $79.38 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Organic growth in interventional devices
Merit's core peripheral intervention, cardiac intervention, and interventional oncology lines serve procedures that continue to shift toward minimally invasive approaches. Management targets low-to-mid single-digit organic constant-currency growth, with Q1 2026 organic growth near 2.7 percent inside total revenue of about $382 million. The recurring, single-use nature of much of the catalog gives revenue a razor-and-blade quality.
2. Bolt-on acquisitions
A defining feature of Merit is its steady cadence of tuck-in acquisitions that add product lines and lift reported growth above the organic rate. Acquired products contributed several points of the roughly 7 percent GAAP growth in Q1 2026. This M&A engine is both a growth driver and a source of integration and capital-allocation risk.
3. Margin expansion and EPS leverage
Merit has pushed its non-GAAP operating margin higher, reaching about 19.7 percent in Q1 2026, its highest first-quarter figure on record. That operating leverage turns mid-single-digit revenue growth into high-single-digit non-GAAP EPS growth, the central mechanism behind the company's earnings story.
4. International and endoscopy expansion
The Endoscopy segment and international markets offer additional runway beyond the mature U.S. cardiovascular base. Global reach also exposes Merit to currency swings and geopolitical shipping disruptions, which trimmed a small amount of Q1 2026 revenue tied to Middle East tensions.
The bear case: what would have to be true for $74.00
The most pessimistic published target is $74.00, -6.8% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Merit Medical Systems is worth if the risks below bite instead of the drivers above.
Merit competes against far larger and better-capitalized device companies including Boston Scientific, Medtronic, Abbott, Teleflex, Becton Dickinson, and Terumo, which can pressure pricing and share. Tariffs weighed on gross margin by roughly 120 basis points in early 2026, and input-cost and currency volatility remain ongoing headwinds. The growth model leans on continued acquisitions, so a slowdown in deal flow or a poorly integrated deal could stall the story. The stock also trades at a premium med-tech multiple, which leaves little room for execution missteps. Regulatory, reimbursement, and product-recall risks are inherent to the medical device industry.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MMSI already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MMSI
11 analysts cover MMSI, with an average target of $90.09 (+13.5% against $79.38) and a split of 9 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the MMSI forecast and price target page.
How is MMSI valued? (as of JULY 2026)
Snapshot for MMSI as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.54B
- Market cap: ~$4.0B
- Net income (TTM): ~$139M
- P/E (GAAP, TTM): ~27x
- 2026 revenue guidance: ~$1.61B to $1.63B
- 2026 non-GAAP EPS guidance: ~$4.01 to $4.15
Merit trades around a mid-20s to high-20s P/E on trailing GAAP earnings, a premium that reflects its consistency and acquisition-driven model. Q1 2026 revenue of about $382 million rose 7 percent year over year, with non-GAAP EPS of $0.94 beating expectations. Full-year 2026 guidance implies roughly 6 to 8 percent revenue growth and mid-to-high single-digit non-GAAP EPS growth.
How do you decide if MMSI is a buy?
Rather than asking whether MMSI is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MMSI indirectly through an index or sector ETF before adding more.
What would change your mind on MMSI
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Organic growth in interventional devices stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: merit competes against far larger and better-capitalized device companies including Boston Scientific, Medtronic, Abbott, Teleflex, Becton Dickinson, and Terumo, which can pressure pricing and share fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MMSI stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MMSI against your real portfolio and see your actual exposure before deciding.
Investing in Merit Medical Systems with AI
Connect the broker you already use and ask Walnut's AI how MMSI fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is MMSI a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Organic growth in interventional devices, with revenue (ttm) at ~$1.54B. The bear case rests on merit competes against far larger and better-capitalized device companies including Boston Scientific, Medtronic, Abbott, Teleflex, Becton Dickinson, and Terumo, which can pressure pricing and share. Analysts covering it are spread from $74.00 to $110.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MMSI?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Merit competes against far larger and better-capitalized device companies including Boston Scientific, Medtronic, Abbott, Teleflex, Becton Dickinson, and Terumo, which can pressure pricing and share. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $74.00, -6.8% from the $79.38 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for MMSI?
+
Organic growth in interventional devices. Merit's core peripheral intervention, cardiac intervention, and interventional oncology lines serve procedures that continue to shift toward minimally invasive approaches. The most optimistic analyst target on MMSI is $110.00, +38.6% from the $79.38 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for MMSI?
+
Merit competes against far larger and better-capitalized device companies including Boston Scientific, Medtronic, Abbott, Teleflex, Becton Dickinson, and Terumo, which can pressure pricing and share. Tariffs weighed on gross margin by roughly 120 basis points in early 2026, and input-cost and currency volatility remain ongoing headwinds. The growth model leans on continued acquisitions, so a slowdown in deal flow or a poorly integrated deal could stall the story. The stock also trades at a premium med-tech multiple, which leaves little room for execution missteps. Regulatory, reimbursement, and product-recall risks are inherent to the medical device industry. The most pessimistic published target is $74.00, -6.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Merit Medical Systems do?
+
Merit Medical Systems designs, manufactures, and markets a broad catalog of single-use and capital medical devices used in minimally invasive procedures.
What would have to change for MMSI to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Organic growth in interventional devices) stalling in the reported numbers rather than in the narrative, the risk above (merit competes against far larger and better-capitalized device companies including Boston Scientific, Medtronic, Abbott, Teleflex, Becton Dickinson, and Terumo, which can pressure pricing and share) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Merit Medical Systems do?
+
Merit develops, manufactures, and markets single-use and capital medical devices used in minimally invasive procedures across interventional cardiology, radiology, oncology, and endoscopy. Its products include catheters, guide wires, stents, inflation devices, and procedure kits.
What exchange is MMSI listed on?
+
MMSI trades on the Nasdaq Stock Market. Merit Medical is headquartered in South Jordan, Utah, and is classified within the medical devices industry of the healthcare sector.
How does Merit Medical make money?
+
Most of Merit's revenue comes from single-use, disposable devices consumed during procedures, which creates recurring demand. The company reports through two segments, Cardiovascular and Endoscopy, and sells globally through direct sales teams and distributors.
Walnut is informational, not investment advice, and gives no verdict on MMSI. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.